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Abstract
Background: Inflammation is a major component of obesity and diabetes, and toll-like receptors
(TLRs) play critical roles in the regulation of inflammation and response to pathogen associated
molecular patterns (PAMPs) and fatty acids in. Although immune cells such as macrophages are
primarily responsible for recognition and clearance of pathogens, adipocytes are also closely
involved in the regulation of innate immunity and inflammation. Whereas it has been demonstrated
that adipocytes respond to TLR4 stimulation with lipopolysacccharide, very little is known about
their response to the TLR2 agonist, peptidoglycan.
Methods:  We investigated the response to peptidoglycan from Staphylococcus aureus in
differentiated 3T3-L1 adipocytes. Real-time PCR analysis was used to quantify the expression of
interleukin 6 (IL6), adiponectin receptors (adipoR1 and adipoR2), toll-like receptor 2 (TLR2) and
4 (TLR2 4). Media level of IL6 was determined with ELISA.
Results: Adipocyte stimulation peptidoglycan induces IL6 expression (P < 0.01). Both siRNA
mediated suppression of TLR2 and immunoneutralization of TLR2 with a TLR2 specific antibody
inhibited response to peptidoglycan (P < 0.05). We also examined the regulation of TLR2 and TLR4
mRNA in peptidoglycan treated cells. Both peptidoglycan and lipopolysaccharide (LPS) robustly
induce TLR2 mRNA expression, whereas TLR4 mRNA is weakly induced by LPS only (P < 0.05).
Additionally, peptidoglycan downregulates the mRNA expression of adiponectin receptors,
adipoR1 and adipoR2 (P < 0.05).
Conclusion: Obesity and type 2 diabetes are associated with increased expression of TLR2, this
receptor could play a significant but previously unrecognized role in the establishment of chronic
inflammation in adipose tissue in obesity.
Background
Adipocytes are integral components of the overall body innate
immune response. This response is mediated mostly by the
highly conserved pattern recognition receptors such as toll-like
receptors (TLRs) and scavenger receptors [1-3]. These recep-
tors and the signaling cascades that they initiate are also
involved in the perpetuation of chronic inflammatory milieu
that characterizes obesity and high fat feeding. Thus, they rep-
resent attractive targets to prevent obesity-induced metabolic
impairments, notably insulin resistance and cardiovascular
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complications [4]. Toll-like receptor 4 remains the most stud-
ied TLR in adipocytes. Our work and that of others have dem-
onstrated that adipocytes respond to inflammatory stimuli
initiated by LPS, the TLR4 ligand [1,5]. Additionally, we have
shown that palmitate, a saturated fatty acid, induces inflam-
mation in adipocytes, and others have shown that fatty acid-
induced inflammation in adipocytes is partly mediated by
TLR4 [6,7]. Toll like receptor 2 is another member of the TLR
family that is constitutively expressed in adipocytes and is rap-
idly induced by LPS and tumor necrosis factor (TNF) α [5].
However, adipocyte response to fungal zymosan, a recognized
ligand for TLR2, has produced mixed results [5,7], and there is
no information on the response of adipocyte to peptidoglycan
and possible impact on inflammatory cytokine production.
Nevertheless, the pattern of expression of TLR2 suggests that
this receptor may be an important component of the inflam-
matory process in obesity. First, TLR2 expression is signifi-
cantly increased in adipose tissue of type 2 diabetic and obese
patients and its expression is upregulated by resistin, an hor-
mone that induces insulin resistance, suggesting TLR2 may be
intricately involved in the regulation of inflammation-
induced insulin resistance than hitherto recognized [8,9].
Indeed, a recent report indicates that obesity induces a subset
of adipocytes to express both TLR2 and TNFα and exposure of
adipocytes to zymosan triggers expression of TNFα [10].
Although mixed results have been observed regarding the
response of adipocytes to fungal zymosan, current evidence
supports a significant role for this receptor in regulating adi-
pose inflammation. Toll-like receptor 2 is the most promiscu-
ous of all the TLRs and is able to recognize multiple ligands
such as fatty acids, fungal zymosan and gram positive bacteria
components (peptidoglycan and teichoic acid), lipoarabi-
nomanan, bacterial lipopeptides, some LPS variants from
gram-negative bacteria, yeast, spirochetes and fungi [11,12].
In addition, this receptor is able to form heterodimers with
other TLRs [13]. Although the identities of its ligands in vivo
have not been clarified, we explored the possibility that
mature adipocytes respond directly in vitro to a gram positive
bacteria component.
Adiponectin is a protein that plays a critical role in the reg-
ulation of glucose and lipid metabolism by increasing glu-
cose uptake in muscle [14], suppressing gluconeogenesis
in the liver [15] increasing fatty acid oxidation in the liver
and muscle [14,15]. Our earlier work in 3T3-L1 adi-
pocytes [16] and porcine macrophages [17] and that of
others in aortic endothelial cell model [18] also provide
clear evidence that adiponectin exerts anti-inflammatory
roles in multiple cell types partly by inhibition of nuclear
factor kappa B (NFκB). Adiponectin exerts its metabolic
effects via two isoforms of its receptor (adipoR1 and
adipoR2) [19]. The regulation of adiponectin bioactivity
is determined at multiples levels including its oligomeri-
zation state [20], and the expression level of its receptors
[21]. Obesity and insulin resistance are associated with a
lower level of circulating adiponectin and reduced con-
centration of the high molecular weight species [20].
Obesity also causes reduced expression of adiponectin
receptors in adipose tissue [22,23]. Thus obesity also
causes a state of adiponectin resistance. However, the
mechanisms that lead to downregulation of adiponectin
receptors in adipose tissue in obesity have not been clari-
fied. Therefore, because obesity is a state of chronic
inflammation that is associated with increased expression
of TLR2 and TLR4, we also tested the hypothesis that acti-
vation of TLR2 and TLR4 in adipocytes represents a mech-
anistic link between inflammation and downregulation of
adiponectin receptors. Because fatty acids are directly
implicated in the induction of inflammation in adi-
pocytes via TLR4 activation [7], and circulating fatty acid
concentrations are elevated in obesity, we further explored
the possibility that fatty acids exert a direct role in the reg-
ulation of TLR2 and TLR4 expression, hence indirectly
influencing the inflammatory response in adipocytes.
We provide evidence herein that differentiated adipocytes
are equipped with the capability to respond directly to
innate immune challenge by gram positive bacteria. This
causes induction of IL6 production, an upregulation of
TLR2 and a downregulation of adiponectin receptors 1
and 2. This additional information represents an exten-
sion of our knowledge of the immunological capabilities
of the adipocyte and a potential interaction with adi-
ponectin action. A deeper understanding of the mecha-
nisms that regulate TLR2 signaling in adipocytes may
contribute to unraveling the causes of obesity-induced
inflammation and insulin resistance.
Methods
Culture of 3T3-L1 Adipocytes
Cells were obtained from ATCC (Manassas, VA) and cul-
tured according to standard conditions. Cells were propa-
gated in high glucose Dulbecco's Modified Eagles Medium
(DMEM) medium (Hyclone, Logan, UT) containing 10%
fetal bovine serum under 5% CO2 and in the presence of
0.5% penicillin-streptomycin mixture (Invitrogen,
Carlsbad, CA). Two days postconfluence (day 0), cells were
induced to differentiate with a medium containing 10%
fetal bovine serum, 1.7 μM insulin, 1 μM dexamethasone,
and 0.5 mM IBMX for 48 hour. Afterwards fresh media con-
taining only insulin and 10% fetal bovine serum was added
for another 48 hours. Subsequent media changes were
done every 48 hours with DMEM containing only 10%
FBS. Cells are typically used for experiments between day
10–12 post differentiation. Before being used for experi-
ments, cells were rinsed twice with serum-free low glucose
(5 mM) DMEM containing 0.1% fatty acid free BSA (treat-
ment media) and kept in this media for 16–24 hours.
Experimental treatment with LPS and Peptidoglycan
Fully differentiated adipocytes in serum free media were
treated with 100 ng/ml lipopolysaccharide (LPS) from E.Journal of Inflammation 2009, 6:8 http://www.journal-inflammation.com/content/6/1/8
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coli and 10 μg/ml peptidoglycan (PEP) from Staphylococ-
cus aureus (Sigma, St Louis, MO) for the indicated time
periods. In experiments with polymyxin B, cells were pre-
treated with 100 μg/ml polymyxin (Sigma) for 30 minutes
and then treated with both LPS and peptidoglycan. We
immunoneutralized both TLR4 and TLR2 by pretreating
cells with 5 μg/ml of azide free functionally active anti-
TLR4 and anti-TLR2 antibodies (eBiosciences, San Diego,
CA) for 1 hour before LPS and peptidoglycan treatments
for additional 6 hours.
Real-time quantitative RT-PCR
Total RNA from treated cells was extracted with Tri Reagent
(Sigma) according to the manufacturer's protocol. The
mRNAs were treated with Turbo Free DNA (Ambion, Austin,
TX) and reverse transcribed into cDNA using Improm II
reverse transcriptase (Promega, Madison, WI). Real-time
PCR was performed using iCycler iQ real-time PCR detection
system (Bio-Rad) with the Faststart SYBR mix (Roche, Indi-
anapolis, IN). Primers for IL6 were: forward primer, 5'-AAC-
GATGATGCACTTGCAGA-3' and reverse, 5'-GAGCATTGG
AAATTGGGGTA-3'. For TLR2, forward primer, 5'-TGCTTTC-
CTGCTGGAGATTT-3' and reverse primer, 5'-TGTAACG-
CAACAGCTTCAGG-3'; TLR4, forward primer, 5'-
TTCAAGACCAAGCCTTTCAG-3' and reverse primer, 5'-CAT-
AGTCCT TCCATGATAGA-3'. Primers for β-actin were for-
ward, 5'-ATGGGTCAGAAGGAC TCCTACG-3' and reverse,
5'-AGTGGTACGACCAGAGGCATAC-3'. AdipoR1, forward,
5'-AACGGGCCATCCATTTTTG-3' and reverse, 5'-
TTAGCCGGG CTACATCAAGG-3'. AdipoR2, forward, 5'-
AGTGTTTTCAGCACGCCCTC-3' and reverse, 5'-GCT-
GAGCTCCACGGATTCTT-3'. The mRNA levels were
obtained from the value of threshold cycle (Ct) for each spe-
cific gene and normalized against the Ct of β-actin.
SiRNA Mediated silencing of TLR2 and TLR4
Adipocytes at day 6 into differentiation were transfected
with the Deliver X® transfection reagent (Panomics, Red-
wood City, CA) with 50 nM siRNA duplexes of either
TLR4 (5'-CCCAAUUGA CUUCAUUCAAGATT-3' and 5'-
UCUUGAAUGAAGUCAAUUGGGTT-3') or TLR2, (5'-
CAAAGUGGUUGUCGCCUGCUUUTT-3' and 5'-AAG-
CAGGCGACAACC ACUUUGTT-3') for 72 hours. A non-
silencing SiRNA duplex (vesirna) (Ambion, Austin, TX)
was used as negative control. Cells were used for experi-
ments immediately after the end of transfection (Day 9
post differentiation).
Pretreatment of adipocytes with specific pharmacological 
inhibitors
To investigate the role of the specific signaling pathways
in the regulation of peptidoglycan mediated cellular
responses, cells were pretreated for 1 hour with 10 μM of
U0126, SP600125 (abbreviated SP) and 50 μg/ml SN50
(Biomol, Plymouth Meeting, PA), specific inhibitors for
p44/42 mitogen activated protein kinase (ERK/p44/
42MAPK), c-Jun N terminal kinase (JNK) and nuclear fac-
tor kappa B (NFκB) respectively. Adipocytes were subse-
quently treated with LPS or peptidoglycan for the
indicated periods.
Fatty Acid Regulation of TLR2 and TLR4
Because obesity is associated with elevated levels of fatty
acids, we investigated whether fatty acids directly regulate
TLR2 and TLR4 mRNA expression. Adipocytes were
treated with 500 μM linoleic acid (LIN) for 6 hours along-
side LPS and peptidoglycan. Additional studies were con-
ducted to determine the effect of Omega 3 fatty acids
docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA) on TLR2 mRNA expression. Adipocytes were pre-
treated with 500 μM of each fatty acid for 3 hours before
LPS or peptidoglycan treatment for another 6 hours. Fatty
acids were complexed with BSA (3:1) before being used,
and BSA was added to control treatments that did not
receive fatty acids.
ELISA for Media IL6
Media concentrations of IL6 were determined in dupli-
cates per sample using a mouse IL6 ELISA kit (Endogen,
Rockford, IL) according to the manufacturer's instruc-
tions. This kit has an assay sensitivity of < 7 pg/ml and an
inter assay and intra assay variation of < 10%.
Statistical Analyses
All data were checked for normality and then analyzed
using the general linear model (GLM) of SAS. When there
was a significant treatment effect as indicated by the F sta-
tistic, a mean separation analysis was performed with the
least-squares mean separation procedure.
Results
Adipocytes respond directly to TLR2 activation by 
peptidoglycan and upregulate the expression and 
secretion of IL6
Since IL6 represents a major inflammatory cytokine that is
over expressed in adipocytes in obesity, we first sought the
possibility of its induction in response to peptidoglycan.
As presented in Figure 1A and 1B, both peptidoglycan and
LPS stimulate a significant upregulation of IL6 mRNA
expression and secretion respectively (P < 0.05). Interest-
ingly, whereas there was a fall in the level of IL6 mRNA in
LPS treated cells after 24 hours of exposure, IL6 mRNA
expression was sustained for the entire 24 hours in pepti-
doglycan treated cells. This may suggest fundamental dif-
ferences in the signaling characteristics of these receptors,
with TLR2 having a chronic effect, longer than TLR4.
TLR4 activation with LPS, but not TLR2 activation with 
peptidoglycan, is inhibited by endotoxin neutralization 
with polymyxin B
To eliminate the possibility that endotoxin contamina-
tion could mediate the inflammatory response to pepti-Journal of Inflammation 2009, 6:8 http://www.journal-inflammation.com/content/6/1/8
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Lipopolysaccharide (LPS) and peptidoglycan (PEP) induce IL6 mRNA expression and protein secretion Figure 1
Lipopolysaccharide (LPS) and peptidoglycan (PEP) induce IL6 mRNA expression and protein secretion. Cells 
were treated with 100 ng/ml LPS and 10 μg/ml peptidoglycan (PEP) for 3, 6 and 24 hours. Media and mRNA were recovered 
for each time period and assayed for IL6 gene expression using RT-PCR (1A) and protein secretion with ELISA (1B). mRNA 
and media concentration of IL6 were increased by LPS and PEP. Bars represent means and ± SEM of this normalized expression 
from 4 different replicates. Bars with different superscripts are different (P < 0.05).
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doglycan that was obtained, cells were pretreated with
polymyxin B to neutralize LPS. As presented in Figure 2,
sequestration of LPS with polymyxin completely abol-
ishes the response to LPS, but does not inhibit peptidog-
lycan effect. This further supports our hypothesis that the
response to peptidoglycan was not mediated by LPS con-
tamination.
Immunoneutralization of TLR2 with a neutralizing 
antibody and suppression of TLR2 with TLR2 specific 
siRNA abolishes inflammatory response to peptidoglycan
Although TLR2 is the recognized receptor for peptidogly-
can, adipocytes express multiple toll receptors and other
classes of scavenger receptors. Therefore, to confirm that
the inflammatory response to peptidoglycan was specific
to TLR2, first we neutralized TLR2 with an immunoneu-
tralizing antibody. As shown in Figure 3A, inhibiting TLR4
with its antibody inhibits the response to LPS as expected
and neutralizing TLR2 completely suppresses the response
of adipocytes to peptidoglycan (P < 0.05). In another set
of experiments, suppression of TLR2 and TLR4 with their
respective siRNAs (Figure 3B) leads to reduction in the
mRNA of both receptors (P < 0.05). However, only TLR2
specific siRNA prevents the response to peptidoglycan
whereas TLR4 siRNA had no effect (Figure 3C) (P < 0.05).
Regulation of peptidoglycan-induced IL6 gene expression 
by p44/42 MAPK, c-JNK and NFκB
We also determined the effect of inhibiting extracellular
signal regulated kinase (ERK), c-Jun N terminal Kinase (c-
JNK) and the nuclear factor kappa B (NFκB) pathways on
the induction of IL6 expression. Our previous work and
that of others have shown that these pathways are impor-
tant in the regulation of IL6 expression in response to
TLR4 activation [1,15]. Inhibition of both the ERK and c-
JNK pathways with their respective inhibitors (U0126 and
SP600125 or SP) suppresses IL6 induction by peptidogly-
can treated cells (Fig. 4A). However, inhibiting NFkB with
the inhibitory peptide (SN-50) did not abrogate IL6
mRNA induction by peptidoglycan.
Polymyxin B inhibits induction of IL6 mRNA by LPS, but had no effect against peptidoglycan Figure 2
Polymyxin B inhibits induction of IL6 mRNA by LPS, but had no effect against peptidoglycan. Cells were treated 
with 100 μg/ml polymyxin B for 30 minutes before treatment with LPS (100 ng/ml) and PEP (10 μg/ml PEP) for 6 hours. Induc-
tion of IL6 gene expression by LPS treatment was significantly suppressed in the presence of polymyxin, but not PEP induction 
of IL6. Bars represent means and ± SEM of this normalized expression from 4 different replicates. Bars with different super-
scripts are different (P < 0.05).
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Effect of immunoneutralization of TLR4 and TLR2 with their respective antibodies and siRNA mediated suppression of TLR2  and TLR4 on IL6 expression Figure 3
Effect of immunoneutralization of TLR4 and TLR2 with their respective antibodies and siRNA mediated sup-
pression of TLR2 and TLR4 on IL6 expression. Cells were treated with 5 μg/ml neutralizing antibodies against TLR2 
(TLR2ab) and TLR4 (TLR4ab) for 1 hour before treatment with LPS (100 ng/ml) and PEP (10 μg/ml) for 6 hours (3A). Both 
antibodies inhibit (P < 0.05) the induction of IL6 mRNA by their respective receptors. In cells treated with TLR2 and TLR4 spe-
cific siRNAs expression of TLR2 and TLR4 was reduced by their respective siRNAs (3B). Induction of IL6 expression by treat-
ment with peptidoglycan was attenuated in cells treated with TLR2 siRNA, but not the negative siRNA (vesirna) or TLR4 
siRNA (3C). Bars represent means and ± SEM of this normalized expression from 4 different replicates. Bars with different 
superscripts are different (P < 0.05).
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Regulation of TLR2 and TLR4 mRNA expression
We also examined the regulation of TLR2 and TLR4
mRNA expression in response to both LPS and peptidog-
lycan to determine if these were subject to regulation to in
response to their respective ligands and fatty acids.
Whereas TLR2 mRNA expression was induced 7 fold by
both LPS and peptidoglycan (Fig. 5A) (P < 0.05), only
minimal upregulation of TLR4 mRNA was obtained (1.5
fold) (Fig. 5B), and in LPS treated cells only. Linoleic acid
treatment did not affect the expression of both receptors.
Because TLR2 was robustly induced by both LPS and pep-
tidoglycan, we examined whether its mRNA expression
was subject to regulation by fatty acids. In adipocytes
treated with DHA and EPA (Fig. 6A), small but significant
(P < 0.05) induction of TLR2 mRNA was observed and
both DHA and EPA treated cells. However, all three fatty
acids additively led to increased TLR2 mRNA expression
in conjunction with peptidoglycan (P < 0.05).
Inhibition of p44/42 MAPK and c-JNK upregulates TLR2 
mRNA
We determinedTLR2 mRNA expression in cells pretreated
with specific inhibitors against p44/42 MAPK, c-JNK and
NFκB. Unlike the case with IL6 expression which was
inhibited when p44/42 and c-JNK were inhibited, there
was an upregulation of TLR2 in the presence of peptidog-
lycan and inhibitors to both p44/42 MAPK and c-JNK
(Fig. 6B). However, as observed for IL6 expression, inhibi-
tion of NFκB did not affect TLR2 expression.
Peptidoglycan downregulates adiponectin receptors 1 and 
2 expression
Because adiponectin is a major adipokine that is involved
in stimulation of glucose uptake and fatty acid oxidation,
we also examined the regulation of the expression of its
receptors, adipoR1 and adipoR2, by peptidoglycan. Both
receptors were significantly downregulated (Figure 7A and
7B) by adipocyte exposure to peptidoglycan (P < 0.05).
Discussion
Adipose tissue plays a significant role in the response to
inflammatory stimuli. This role is conserved from dro-
sophila to mammals, and because of their strategic loca-
tion around organs, adipocytes are able to participate in
the recognition and neutralization of multiple pathogens.
Thus adipocytes facilitate a robust innate immune defense
system [1,24,25]. The innate immune response mediated
by adipocytes is primarily mediated by adipokines
Inhibition of extracellular signal regulated kinase (ERK) and JNK inhibits IL6 induction by peptidoglycan Figure 4
Inhibition of extracellular signal regulated kinase (ERK) and JNK inhibits IL6 induction by peptidoglycan. Both 
ERK and JNK were inhibited by treating cells with 10 μM of U0126 and SP600125(SP) and 50 μg/ml of the NFkB inhibitory pep-
tide (SN50) for 30 minutes before treating with LPS (100 ng/ml) and PEP (10 μg/ml) for 6 hours. Inhibition of ERK and JNK, but 
not NFκB, inhibited IL6 induction by peptidoglycan. Bars represent means and ± SEM of this normalized expression from 4 dif-
ferent replicates. Bars with different superscripts are different (P < 0.05).
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Regulation of TLR2 and TLR4 mRNA expression by LPS, peptidoglycan and linoleic acid Figure 5
Regulation of TLR2 and TLR4 mRNA expression by LPS, peptidoglycan and linoleic acid. Expression of both TLR2 
(5A) and TLR4 (5B) was determined in cells treated with LPS (100 ng/ml), peptidoglycan (10 μg/ml) and linoleic (500 μM) acid 
for 6 hours. Significant induction of TLR2 (5A) (approx.7 fold) and TLR4 (5B) (1.5 times) was obtained. Bars represent means 
and ± SEM of this normalized expression from 4 different replicates. Bars with different superscripts are different (P < 0.05).
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Regulation of TLR2 induction peptidoglycan by fatty acids and pharmacological inhibitors of ERK (p44/42 MAPK), JNK and  NFκB Figure 6
Regulation of TLR2 induction peptidoglycan by fatty acids and pharmacological inhibitors of ERK (p44/42 
MAPK), JNK and NFκB. In cells pretreated with 500 μM linoleic acid (LIN), eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA) and then treated with peptidoglycan (6A), TLR2 mRNA expression was further additively upregulated in the 
presence of the fatty acids and peptidoglycan. Additionally, in cells were pretreated with the specific inhibitors, 10 μM U0126 
and SP600125 (SP) and 50 μg/ml SN50 before peptidoglycan treatment for 6 hours. Inhibition of ERK and JNK, but not NFκB 
(6B), additively upregulated peptidoglycan induced TLR2 expression. Bars represent means and ± SEM of this normalized 
expression from 4 different replicates. Bars with different superscripts are different (P < 0.05).
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released in response to inflammatory stimuli [26,27].
Although the expression of TLR2 in adipocytes suggests a
capability to respond to TLR2 ligands, [5,7,10], little is
known regarding the activation of inflammatory response
by peptidoglycan in adipocytes. We have provided evi-
dence herein that adipocytes respond directly to TLR2
activation with the peptidoglycan component of gram
positive bacteria. The ability of adipocytes to recognize
gram positive bacteria component fills a critical gap
regarding the capability of adipocytes to neutralize both
classes of bacteria pathogens and demonstrates the versa-
tility of immune reaction mediated by the adipocytes. The
recent evidence that fatty acids act as endogenous ligands
for TLR2 in hypertrophic adipose tissue leading to the acti-
vation of a subset of adipose tissue macrophages [28] sup-
ports a relevant role for TLR2 in vivo. Since fatty acid
concentrations are elevated in obesity, fatty acids could be
the major endogenous ligands for TLR2 in adipose tissue.
Whereas TLR4 activation induces a rapid acute response,
the inflammatory response to TLR2, demonstrated by the
induction of IL6 in our case, is slower, but surprisingly
prolonged. Therefore, although activation of both recep-
tors elicits an inflammatory response, TLR2 induces a
chronic inflammatory state. Although peptidoglycan rec-
ognition protein (PGRP) and NOD have been shown to
mediate peptidoglycan response in some cell types [29],
their role in mediating the response obtained in this
experiment is limited because immunoneutralization
with a TLR2 specific antibody totally ablates response to
peptidoglycan, and a TLR2 specific siRNA drastically
(approx. 80%) reduces IL6 induction by peptidoglycan.
Obesity and type 2 diabetes are associated with a chronic
low grade systemic and adipose tissue inflammation
[30,31]. Interestingly, obesity and type 2 diabetes are also
associated with increased expression of TLR2, and obesity
induces the expression of a subset of adipocytes that over
express both TLR2 and TNFα [8,10]. The reduction in the
expression of adiponectin receptors in response to TLR2
activation with peptidoglycan also agrees with the finding
that these receptors are downregulated in adipose tissue of
obese and insulin resistant mice [22]. This raises the pos-
sibility that activation of TLR2 in obesity may contribute
to a state of adiponectin resistance in obesity. Because adi-
ponectin exerts anti-inflammatory effects [16], a reduc-
tion in the expression of its receptors could attenuate this
critical role of adiponectin. Therefore, TLR2 may be an
important player in the perpetuation of inflammation
that characterizes obesity.
Our work and that of others have shown that multiple sig-
naling pathways mediate LPS induction of IL6 [1,23,32].
These pathways include NFκB, c-JNK, ERK, inhibitory G
protein and PKC mediated processes. Toll like receptors
activate similar but distinct signaling pathways due to
their ability to recruit different adapter proteins. TLR2 is
able to recruit TIRAP/Mal, and this allows it to regulate the
Regulation of adiponectin receptors, adipoR1 and adipoR2, by peptidoglycan Figure 7
Regulation of adiponectin receptors, adipoR1 and adipoR2, by peptidoglycan. Acute treatment of adipocytes with 
peptidoglycan (10 μg/ml) for 3 hours leads to a significant downregulation of adipoR1 (7A) and adipoR2 (7B). Bars represent 
means and ± SEM of this normalized expression from 3 different replicates. Bars with different superscripts are different (P < 
0.05).
a a
A  B 
b
bJournal of Inflammation 2009, 6:8 http://www.journal-inflammation.com/content/6/1/8
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expression of a distinct set of inflammatory genes such as
IL6, TNFα and IL12 [33-35]. Our work has shown that
inhibition of NFκB failed to suppress induction of IL6 by
peptidoglycan and also had no effect on TLR2 mRNA
expression. It is unknown whether this observation is
unique to the 3T3-L1 adipocytes or related to our experi-
mental conditions, but parallels the inability of NFκB
inhibition to suppress IL6 induction by LPS in myocytes
[23]. However, additional studies will be needed to fully
characterize the uniqueness of the signaling characteristics
of TLR2 in adipocytes in comparison with other toll recep-
tors.
The strong induction of TLR2 mRNA by both LPS and
peptidoglycan that was observed in this study clearly sup-
ports a role for TLR2 as a strong marker of inflammation
in adipocytes. This corroborates the induction of TLR2,
but not TLR4, by LPS in mouse splenic macrophages [35].
Since obesity is an inflammatory condition that is also
associated with elevated TLR2 expression in adipose tis-
sue, adipocyte TLR2 may indeed mediate part of the
inflammatory environment that characterizes obesity
[8,10,30]. Therefore, targeting TLR2 may contribute to
prevention of obesity-induced inflammation. Since obes-
ity is also associated with elevated fatty acid levels, the
induction of TLR2 expression by both DHA and EPA indi-
vidually and additively with peptidoglycan and the addi-
tive induction of TLR2 by both linoleic acid and
peptidoglycan suggests that fatty acids may be partly
responsible for the upregulation of TLR2 in obesity. This
also suggests that regulation of TLR2 mediated cellular
responses may be fatty acid specific. Elevated fatty acid
concentrations in obesity may amplify the inflammatory
cascade that is induced by yet unidentified endogenous
ligands for TLR2. Although omega-3 fatty acids, EPA and
DHA at moderate levels are known to exert anti-inflam-
matory effects, elevated levels of these fatty acids in circu-
lation has been demonstrated to cause increased
inflammation characterized by increased macrophage
infiltration into adipose tissue [36]. Therefore, the levels
of these fatty acids as utilized in this experiment mimic
more closely the hyperlipidemic condition that is charac-
terized by elevated fatty acid concentrations. The additiv-
ity of effects of fatty acids and peptidoglycan on the
induction of TLR expression suggests that under the
hyperlipidemic conditions of obesity fatty acids and lig-
ands of TLRs may co-operate to amplify the inflammatory
state by further increasing the expression of TLRs. This
may be a mechanism to prevent desensitization to the
effects of TLR ligands in obesity.
Interestingly, whereas inhibition of p44/42 MAPK and c-
JNK suppressed peptidoglycan induction of IL6, it ampli-
fies the induction of TLR2 mRNA by peptidoglycan. This
observation agrees with the upreguation of TLR2 mRNA
by p44/42 MAPK inhibition with PD 98059 in RAW 264.7
macrophages [35]. Furthermore, it indicates that these
kinase pathways, although they mediate positively the
induction of IL6 by peptidoglycan, they may also be
involved in a negative feedback mechanism to prevent an
upregulation of TLR2 during inflammation, perhaps to
prevent on overzealous inflammatory reaction.
The downregulation of expression of both adiponectin
receptors by peptidoglycan parallels the reduction of sol-
uble adiponectin receptor expression after the administra-
tion of LPS to human subjects [37] and suggests that TLR2
activation in obesity may partly be responsible for the
downregulation of adiponectin receptor expression in
adipose tissue in obesity [22]. Therefore, this may impli-
cate TLR2 in phenomenon of obesity-induced adiponec-
tin resistance. Because reduced expression of adiponectin
receptors correlates with reduced AMPK activation, TLR2
activation may play an active role in the worsening insulin
resistance in obesity.
In conclusion, we have provided evidence that adipocytes
are able to respond to gram positive bacteria component
in a TLR2 dependent manner and the response to TLR2
stimulation appears to perpetuate a chronic immune
response. Since TLR2 expression is induced in obesity and
type 2 diabetes, TLR2 may play a prominent role in the
initiation of obesity induced inflammation. The use of
TLR2 knockout animal models will provide further
insight into this mechanism. An understanding of the role
of TLR2 and its interactions with other receptors in the
adipocyte may yield significant insights into the regula-
tion of inflammation in obesity and may help in the
search for new therapeutic targets against obesity-induced
impairment of insulin signaling.
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